Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

20.7%

6 terminated/withdrawn out of 29 trials

Success Rate

71.4%

-15.1% vs industry average

Late-Stage Pipeline

3%

1 trials in Phase 3/4

Results Transparency

27%

4 of 15 completed trials have results

Key Signals

5 recruiting4 with results

Enrollment Performance

Analytics

N/A
11(50.0%)
Early Phase 1
5(22.7%)
Phase 2
4(18.2%)
Phase 4
1(4.5%)
Phase 1
1(4.5%)
22Total
N/A(11)
Early Phase 1(5)
Phase 2(4)
Phase 4(1)
+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (29)

Showing 20 of 29 trials
NCT06223971Early Phase 1Completed

Long COVID-19 [11C]CPPC Study

Role: collaborator

NCT03495115Not ApplicableCompleted

Comparing Restriction Spectrum Imaging (RSI) to Conventional and Abbreviated Breast MRI for Breast Cancer Screening

Role: collaborator

NCT05121961Not ApplicableCompleted

Treatment for Sacroiliac Joint Pain Using Platelet-rich Plasma (PRP) Versus Steroid/Anesthetic

Role: collaborator

NCT06225414Not ApplicableCompleted

Empowering Hispanic Patients' Lung Cancer Screening Uptake (Empower Latinx)

Role: collaborator

NCT02701153Not ApplicableRecruiting

Phase II Study of 5-Day Hypofractionated Preoperative Radiation Therapy for Soft Tissue Sarcomas: Expansion Cohort

Role: collaborator

NCT04875884Not ApplicableRecruiting

Optimized MRI of Patients With Hip Arthroplasty

Role: collaborator

NCT07040163Early Phase 1Active Not Recruiting

Evaluation of Ketamine/Midazolam Sedation vs. Fentanyl/Midazolam Sedation for Image-Guided Percutaneous Procedures in Interventional Radiology

Role: collaborator

NCT04354064Recruiting

Circulating Tumor DNA (ctDNA) for Early Treatment Response Assessment of Solid Tumors

Role: collaborator

NCT06076538Recruiting

PET/MR for Characterization of Renal Masses (RMs)

Role: collaborator

NCT07227792Not ApplicableRecruiting

Tongue-out Radiation Therapy (TORT) for the Mitigation of Radiotherapy-related Toxicities in Patients With Head and Neck Cancer

Role: collaborator

NCT05483023Phase 2Withdrawn

18-fluorofuranylnorprogesterone (FFNP) PET/MRI as a Potential Biomarker of Response to Progesterone Therapy

Role: collaborator

NCT04050683Not ApplicableCompleted

Evaluation of Hemodynamic Parameters Following Transjugular Intrahepatic Portosystemic Shunt (TIPS)

Role: collaborator

NCT01668953Not ApplicableTerminated

Comparison of Platelet Rich Plasma and Alternative Therapies for the Treatment of Tennis Elbow (Lateral Epicondylitis)

Role: collaborator

NCT04976257Early Phase 1Completed

Pharmacokinetics of IA and IV Ga68-PSMA-11 Infusion

Role: collaborator

NCT05157451Phase 2Withdrawn

Y-90 Versus SBRT for Inoperable HCC

Role: collaborator

NCT03294148Not ApplicableCompleted

Mind-body Treatments for Chronic Back Pain

Role: collaborator

NCT05718115Unknown

Deep Learning Radiogenomics For Individualized Therapy in Unresectable Gallbladder Cancer

Role: collaborator

NCT03857087Completed

68Ga-PSMA PET in Diagnosing Metastasis in Patients With Ovarian Cancer

Role: collaborator

NCT03112434Completed

Muscle Elastography in Spastic Cerebral Palsy

Role: collaborator

NCT03280277Early Phase 1Terminated

Ferumoxytol-Enhanced MRI in Imaging Lymph Nodes in Patients With Locally Advanced Rectal Cancer

Role: collaborator